India Fat-Loss Drug Sales Slow After Early Spike From Generics
2026-07-08 07:55:34
Growth in India’s obesity- and diabetes-drug market is slowing just months after an early surge sparked by the launch of generic semaglutide products, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
